Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Agashi, Kapil (2010)
Languages: English
Types: Unknown
Herein, two translational issues related to the development of cell therapy discoveries into therapeutic products, are addressed. Firstly, analysis of whether the manipulations required to transfer cells from cell culture conditions to a target tissue affect cellular characteristics was performed. It was shown that processing primary murine mesenchymal stem cells (MSCs) into a concentrated cell suspension, drawing them up into a syringe and immediately ejecting them, caused a significant viability decrease. Leaving the cells within the syringe chamber at room temperature for prolonged time periods caused to a further decrease in viability. However, cells that were viable post-ejection were found to be functional with regard to their ability to attach and proliferate. Reducing the ejection rate or using the antioxidant n-acetyl cysteine did not significantly improve viability, although using a wider bore 22g needle did improve viability. Secondly, the feasibility of a cell transportation device that could store viable cells under room conditions was assessed. The development of such a transportation device would remove the need to cyropreserve cells during transit, which has many flaws. Human MSCs were found to enter a reversible proliferative arrest phase whilst under room conditions, allowing them to be stored for up to 11 days, before rapidly decreasing in viability. The accumulation of ammonia was identified within the cultures, and the introduction of a zeolite material was found to partially remove this ammonia and improve viability over 7 days. A means of developing a concentrated cell culture media, using a freeze-drying technique, was found not to comprise cell viability, whilst allowing the nutrient volume to be reduced, thus potentially making the transportation device more compact. However, the introduction of a modified release nutrient gel, consisting of alginate, did not provide any significant effect on viability.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Salter, B. & Harvey, O. Stem Cell Innovation in the USA: the benefits of the minimal state. Regenerative Medicine 3, 597-610 (2008).
    • Overfield, J., Dawson, M. & Hamer, D. Transfusion Science. 2nd edn, (Scion Publishing Ltd., 2007).
    • Kobayashi, N. Artificial Cell for the Development of Cell Therapy. Cell Transplantation 17, 3-9 (2008).
    • Shapiro, A. M. J. et al. International Trial of the Edmonton Protocol for Islet Transplantation. New England Journal of Medicine 355, 1318-1330 (2006).
    • Jiang, J. J. et al. Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells 25, 1940-1953 (2007).
    • Jackson, L., Jones, D. R., Scotting, P. & Sottile, V. Adult mesenchymal stem cells: Differentiation potential and therapeutic applications. Journal of Postgraduate Medicine 53, 121-127 (2007).
    • De Bari, C. & Dell'Accio, F. Cell Therapy: A challenge in modern medicine. Bio-Medical Materials and Engineering 18, S11-S17 (2008).
    • Dietz, A., Padley, D. & Gastineau, D. Infrastructure development for human cell therapy translation. Clinical Pharmacology & Therapeutics 82, 320-324 (2007).
    • Banfi, A. et al. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy. Experimental Hematology 28, 707-715 (2000).
    • Engelmann, M. & Franz, W. Stem Cell Therapy after myocardial infarction: Ready for clinical application? Current Opinion in Molecular Therapeutics 8, 396-414 (2006).
    • Hernigou, P., Poignard, A., Baeujean, F. & Rouard, H. Percutaneous Autologous Bone-Marrow Grafting for Nonunions. Journal of Bone & Joint Surgery America 87, 1430-1437 (2005).
    • Zhao, R. & Daley, G. From fibroblasts to iPS cells: induced pluripotency by defined factors. Journal of Cellular Biochemistry 105, 949-955 (2008).
    • Kaji, K. et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458, 771-775 (2009).
    • Knoepfler, P. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 27, 1050-1056 (2009).
    • Fändrich, F., Dresske, B., Bader, M. & Schulze, M. Embryonic stem cells shar immune-privileged features relevant for tolerance induction. Journal of Molecular Medicine 80, 343-350 (2002).
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article